Combination treatment with durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) leads to higher rates of pathologic complete response (pCR) in patients with resectable gastric cancer (GC) or gastroesophageal junction cancer (GEJC), with the benefit universally observed regardless of geographic location, according to the subgroup analysis of the phase III MATTERHORN study.
Bacterial respiratory tract infection normally occurs in infants requiring early intubation in the emergency department (ED) for viral bronchiolitis, according to a study. However, respiratory bacterial codetection appears to shorten the duration of mechanical ventilation (MV) and length of stay (LOS) of these patients in the intensive care unit (ICU).
First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.
In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.
Treatment-emergent (TE) antidrug antibodies (ADA) do not show any influence on the pharmacokinetics or efficacy of tirzepatide (TZP), as shown in a study. Most of the hypersensitivity or injection site reactions in patients with TE ADA are either mild or moderate in severity.
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).
Treatment with reteplase appears more effective than alteplase in patients with acute ischaemic stroke (AIS) who have been treated within 4.5 hours of symptom onset, according to the results of RAISE, a phase III multicentre, open-label, randomized controlled, noninferiority trial.
In anticoagulation-associated intracerebral haemorrhage (ICH), earlier administration of reversal treatments is associated with reduced in-hospital mortality or discharge to hospice, according to data presented at ISC 2024.